J.P. Morgan Maintains a Buy Rating on Clovis Oncology

By Ryan Adsit

In a report issued on June 19, Cory Kasimov from J.P. Morgan maintained a Buy rating on Clovis Oncology (NASDAQ: CLVS), with a price target of $111. The company’s shares opened today at $94.29, close to its 52-week high of $94.97.

According to TipRanks.com, Kasimov is a 1-star analyst with an average return of -0.2% and a 40.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Global Blood Therapeutics, and Karyopharm Therapeutics.

Currently, the analyst consensus on Clovis Oncology is Strong Buy and the average price target is $76.50, representing a -18.9% downside.

In a report issued on June 13, Leerink Swann also initiated coverage with a Buy rating on the stock with a $85 price target.

The company has a one year high of $94.97 and a one year low of $11.57. Currently, Clovis Oncology has an average volume of 1.86M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Clovis Oncology, Inc. is a biopharmaceutical company which focuses on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. The company has three product candidates in its clinical development pipeline: Rociletinib, Rucaparib and Lucitani. Clovis Oncology was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.